Basic Information
| LncRNA/CircRNA Name | NMR |
| Synonyms | NA |
| Region | GRCh38_1:6724637-6730012 |
| Ensemble | ENSG00000228750 |
| Refseq | NR_104620 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | esophageal squamous cell carcinoma |
| ICD-0-3 | NA |
| Methods | in vitro knockdown |
| Sample | esophageal squamous cell carcinoma tissues |
| Expression Pattern | down-regulated |
| Function Description | We identified a novel NSUN2 methylated lncRNA (NMR), which was significantly upregulated in esophageal squamous cell carcinoma (ESCC), functioned as a key regulator of ESCC tumor metastasis and drug resistance. Upregulation of NMR correlated with tumor metastasis and indicated poor overall survival in ESCC patients. Functionally, NMR could promote tumor cell migration and invasion, inhibit cisplatin-induced apoptosis and increase drug resistance in ESCC cells. Mechanistically, transcription of NMR could be upregulated by NF-kB activation after IL-1B and TNF-a treatment. NMR was methylated by NSUN2 and might competitively inhibit methylation of potential mRNAs. |
| Pubmed ID | 29763634 |
| Year | 2018 |
| Title | Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma. |
External Links
| Links for NMR | GenBank HGNC NONCODE |
| Links for esophageal squamous cell carcinoma | OMIM COSMIC |